GILD vs SYNC.L
GILD: A global biopharmaceutical leader advancing life-saving treatments in HIV, liver disease, and oncology. SYNC.L: A London-listed investment firm that creates and builds pioneering life science companies, with a specialized focus on advanced therapies and oncology.
Side-by-side fundamentals
| Metric | GILD | SYNC.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $131.76 | £1.07 | |
| Market cap as of 2026-08-06 | $163.6B | n/a | |
| P/E as of 2026-08-06 | 17.55 | n/a | |
| PEG as of 2026-08-06 | 2.53 | n/a | |
| Net margin as of 2026-08-06 | +31.0% | n/a | |
| Gross margin as of 2026-08-06 | +79.4% | n/a | |
| Operating margin as of 2026-08-06 | +34.9% | n/a | |
| ROE as of 2026-08-06 | +42.2% | n/a | |
| ROA as of 2026-08-06 | +16.1% | n/a | |
| Debt / equity as of 2026-08-06 | 0.94 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +3.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-08-06 | +2.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-06 | 0.33 | n/a | |
| 1-year return as of 2026-08-05 close | +17.2% | +10.7% | GILD higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.